Czechia· CZ-0193817

RYZODEG

A insulin degludec und insulin aspart product containing insulin degludec + insulin aspart, registered in Czechia by Novo Nordisk A/S, Bagsvaerd. The same ATC class is registered in 9 of our 19 countries.

ATC A10AD06

Checked against SÚKL (Czech Republic) on

Informational only — not a medical device.

SOURCE REGISTER · CZSÚKL (Czech Republic)normalisedRYZODEGATCA10AD06REGISTER NO.CZ-0193817PACKS LISTED1CHECKEDSeptember 28, 2026

Where it is registered

Insulin degludec und insulin aspart is registered in 9 of 19 countries.

Countries holding a registration under ATC A10AD06 (insulin degludec und insulin aspart), each read from that country’s own register.

  • This record: Czechia, from SÚKL (Czech Republic)
  • 6 of them publish a price we can compare per daily dose

Insulin degludec und insulin aspart · ATC A10AD06

9 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

SÚKL (Czech Republic)
Active substance
INSULIN DEGLUDEC + INSULIN ASPART
Manufacturer
Novo Nordisk A/S, Bagsvaerd
Country
Czechia (CZ)
ATC code
A10AD06
ATC class
Insulin degludec und Insulin aspart
Defined daily dose
40 E, P
Reimbursed
Not published by this register
Source register
SÚKL (Czech Republic)
Last checked
September 28, 2026

Packs & prices · 1

1 priced
  • cz_kod_sukl
    0193817
    5X3ML
    CZK 2575.51

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Insulin degludec und insulin aspart in 7 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All insulin degludec und insulin aspart products

Authorised across Europe · EMA

The same active substance is authorised in 2 EEA countries. Names it is sold under:

  • Iceland · Ryzodeg Flexpen, Ryzodeg Flextouch
  • Norway · Ryzodeg Flexpen, Ryzodeg Flextouch

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of SÚKL (Czech Republic). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/0346851e-393a-483a-8dcd-3e2fd69a06cc
GET /v1/drugs/0346851e-393a-483a-8dcd-3e2fd69a06cc?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "INJ SOL ZVL",
  "source": "sukl",
  "strength": "100U/ML",
  "pack_size": "5X3ML",
  "substance": "INSULIN DEGLUDEC + INSULIN ASPART",
  "cz_kod_sukl": "0193817",
  "product_type": "BT",
  "substance_codes": "18626,15384",
  "registration_state": "R",
  "registration_number": "EU/1/12/806/007"
}

See everything about insulin degludec und insulin aspart.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.